Amatech
A medical device company specializing in 3D-printed biodegradable vascular stents and implants.
- CEO / Founder
- Liu Qing
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $51.0M
- Latest Round
- Series D
- Key Investors
- SDIC Venture Capital, China Reform Holdings, Beijing State-owned Assets Management (BSAM), Haidian Science & Technology Financial Capital Group
Technology & Products
Key Products
["AMSorb Bioresorbable Coronary Scaffold","Bioresorbable Peripheral Vascular Stents","3D Printing Medical Device Manufacturing Platform"]
Technological Advantage
Proprietary 3D printing process allows for complex stent geometries and optimized mechanical properties that are difficult to achieve with traditional manufacturing, enabling better biocompatibility and degradation control.
Differentiation
Value Proposition
Provides bioresorbable scaffolds that offer temporary support to blood vessels and then dissolve, reducing long-term risks associated with permanent metal stents.
How They Differentiate
Proprietary multi-nozzle precision 3D printing technology that enables thinner struts and complex geometries compared to traditional laser-cut polymer stents.
Market & Competition
Target Customers
Hospitals, cardiovascular surgeons, and patients with coronary or peripheral artery diseases.
Industry Verticals
["Medical Devices","Healthcare","3D Printing"]
Competitors
Lepu Medical (NeoVas), MicroPort Scientific (Firesorb), Biotronik (Magmaris)
Growth & Milestones
Growth Metrics
Transitioned from R&D to late-stage clinical trials; multiple products granted NMPA 'Green Channel' status.
Major Milestones
["World's first 3D-printed biodegradable vascular stent to enter clinical trials (2019)","Completed Series D funding of over 200 million RMB (2022)","Designated as a National High-Tech Enterprise in China"]
Notable Customers
Fuwai Hospital, Beijing Anzhen Hospital